Online citations, reference lists, and bibliographies.

High-throughput Screens Identify MicroRNAs Essential For HER2 Positive Breast Cancer Cell Growth.

Suvi-Katri Leivonen, K. Sahlberg, R. Mäkelä, E. U. Due, O. Kallioniemi, A. Børresen-Dale, M. Perälä
Published 2014 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
MicroRNAs (miRNAs) are non-coding RNAs regulating gene expression post-transcriptionally. We have characterized the role of miRNAs in regulating the human epidermal growth factor receptor 2 (HER2)-pathway in breast cancer. We performed miRNA gain-of-function assays by screening two HER2 amplified cell lines (KPL-4 and JIMT-1) with a miRNA mimic library consisting of 810 human miRNAs. The levels of HER2, phospho-AKT, phospho-ERK1/2, cell proliferation (Ki67) and apoptosis (cPARP) were analyzed with reverse-phase protein arrays. Rank product analyses identified 38 miRNAs (q < 0.05) as inhibitors of HER2 signaling and cell growth, the most effective being miR-491-5p, miR-634, miR-637 and miR-342-5p. We also characterized miRNAs directly targeting HER2 and identified seven novel miRNAs (miR-552, miR-541, miR-193a-5p, miR-453, miR-134, miR-498, and miR-331-3p) as direct regulators of the HER2 3'UTR. We demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases). miR-342-5p specifically inhibited HER2-positive cell growth, as it had no effect on the growth of HER2-negative control cells in vitro. Furthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts. In conclusion, we have identified miRNAs which are efficient negative regulators of the HER2 pathway that may play a role in vivo during breast cancer progression. These results give mechanistic insights in HER2 regulation which may open potential new strategies towards prevention and therapeutic inhibition of HER2-positive breast cancer.
This paper references
microRNA-205 regulates HER3 in human breast cancer.
M. Iorio (2009)
A microRNA expression signature of human solid tumors defines cancer gene targets
S. Volinia (2006)
A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence
J. Forman (2008)
Variance stabilization applied to microarray data calibration and to the quantification of differential expression
W. Huber (2002)
Analysis of cell-based RNAi screens
M. Boutros (2006)
Regression of murine lung tumors by the let-7 microRNA
Phong Trang (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
Silencing of microRNAs in vivo with ‘antagomirs’
Jan Krützfeldt (2005)
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
J. Foekens (2008)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
A. Wolff (2014)
Endogenous human microRNAs that suppress breast cancer metastasis
S. Tavazoie (2008)
PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
N. Hynes (2009)
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Marit Synnestvedt (2013)
MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation
Y. Tay (2008)
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Diana M. Cittelly (2010)
miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
E. Enerly (2011)
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis
Y. Yao (2012)
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
Jason F. Wiggins (2010)
MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship
Amy E Pasquinelli (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga (2012)
miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer*
Michael R. Epis (2009)
17q12-21 - the pursuit of targeted therapy in breast cancer.
Ronan W Glynn (2010)
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Janaiah Kota (2009)
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b*
G. Scott (2007)
The shaping and functional consequences of the microRNA landscape in breast cancer
H. Dvinge (2013)
ErbB receptors and signaling pathways in cancer.
N. Hynes (2009)
MicroRNA gene expression deregulation in human breast cancer.
M. Iorio (2005)
Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6
J. Kurebayashi (1999)
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer
A. Lowery (2008)
Most mammalian mRNAs are conserved targets of microRNAs.
Robin C Friedman (2009)
ErbB2 down-regulates microRNA-205 in breast cancer.
Ryohei Adachi (2011)
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
F. Yu (2007)
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
Päivi Östling (2011)
LNA-mediated microRNA silencing in non-human primates
J. Elmén (2008)
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.
Q. Pan (2005)
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.
Fumitaka Takeshita (2010)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
K. Berns (2007)
Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer
Stefan Uhlmann (2012)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.
Kristine Kleivi Sahlberg (2013)
Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures.
John S. Tsang (2010)
Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.
Alessandra Magnifico (2007)
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
R. Juliano (2008)
Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR
J. R. Lytle (2007)
Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
Shuang Dou (2012)
RETRACTED: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis
Scott Valastyan (2009)
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines
S-K Leivonen (2009)
miRBase: tools for microRNA genomics
S. Griffiths-Jones (2008)
J-Express: exploring gene expression data using Java
B. Dysvik (2001)

This paper is referenced by
A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth
Yogin Patel (2016)
Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management
Eleni van Schooneveld (2015)
Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
Katia Grillone (2020)
Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel
Zhan Yang (2017)
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
M. K. Nygren (2014)
MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression
Merav Kedmi (2015)
Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1
T. Que (2015)
MiR-199 b-5 p suppresses proliferation and invasion of non-small cell lung cancer ( NSCLC ) via HER 2 / PI 3 K / Akt pathway
Weijun Chen (2016)
The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.
Afsane Bahrami (2018)
MicroRNA: a connecting road between apoptosis and cholesterol metabolism
Yogita K Adlakha (2016)
MicroRNA Networks in Breast Cancer Cells.
Andliena Tahiri (2018)
MicroRNA-491 regulates the proliferation and apoptosis of CD8+ T cells
Ting Yu (2016)
A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance.
Emmanuel I. Papadopoulos (2018)
miR‐541 suppresses proliferation and invasion of squamous cell lung carcinoma cell lines via directly targeting high‐mobility group AT‐hook 2
L. Xu (2018)
A potential risk factor of essential hypertension in case-control study: Circular RNA hsa_circ_0037911.
Xingjie Bao (2018)
Exploiting microRNAs As Cancer Therapeutics
T. Robb (2017)
MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells
James N Fisher (2015)
Predicting microRNA-disease associations by integrating multiple biological information
W. Lan (2015)
No Functional Role for microRNA-342 in a Mouse Model of Pancreatic Acinar Carcinoma
James Dooley (2017)
Primate‐specific miRNA‐637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression
R. Xu (2018)
Recent progress in HER2 associated breast cancer.
Wei-jia Wang (2015)
Sevoflurane inhibits the migration and invasion of glioma cells by upregulating microRNA-637.
Wenbo Yi (2016)
Downregulation of miR-552 in hepatocellular carcinoma inhibits cell migration and invasion, and promotes cell apoptosis via RUNX3
Ying Ma (2019)
Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2.
Qian Zhou (2020)
Circular RNA hsa-circ-0012129 Promotes Cell Proliferation and Invasion in 30 Cases of Human Glioma and Human Glioma Cell Lines U373, A172, and SHG44, by Targeting MicroRNA-661 (miR-661)
Gang Xie (2018)
MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction
Farah Nassar (2017)
Development of nanoparticle platform for therapeutic siRNA and drug delivery to breast cancer
Worapol Ngamcherdtrakul (2015)
MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
Anna Aakula (2015)
SCD rs41290540 single‐nucleotide polymorphism modifies miR‐498 binding and is associated with a decreased risk of coronary artery disease
Zhou Liu (2020)
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
Marijn T. M. van Jaarsveld (2015)
MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo.
X. Peng (2014)
miRNAs in control of oncogenic signaling in breast cancer cells
Annabell Bischoff (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar